Aura 2016 Supplementary data

Table S4.23 Pseudomonas aeruginosa resistance, by clinical setting, 2014

Antimicrobial	Public hospitals and health services, % resistance (n)	Private hospitals, % resistance (n)	Community, % resistance (n)	Residential aged care facilities, % resistance (n)
Ampicillin	na	100.0 (2552)	100.0 (8444)	100.0 (1211)
Piperacillin–tazobactam	10.3 (9101)	na	na	na
Cefazolin	na	na	100.0 (6692)	na
Ceftazidime	7.1 (9194)	4.6 (2551)	1.8 (8430)	2.5 (1212)
Gentamicin	8.9 (9250)	2.5 (2569)	2.6 (8463)	2.5 (1216)
Ciprofloxacin	9.4 (9258)	na	2.8 (6436)	na
Meropenem	6.4 (9194)	na	0.6 (6651)	na
Trimethoprim–sulfamethoxazole	na	na	99.6 (6683)	na

na = not available (either not tested or tested against an inadequate number of isolates)

Sources: OrgTRx, Queensland (public hospitals and health services); SNP (private hospitals, community and residential aged care facilities)

Table S4.24 Salmonella species (nontyphoidal) resistance, by specimen source, 2014

Antimicrobial	Blood, % resistance (n)	Faeces, % resistance (n)	Other, % resistance (n)	Total, % resistance (n)
Ampicillin	6.7 (180)	7.7 (2421)	7.7 (115)	7.6 (2716)
Amoxicillin–clavulanate	0.0 (91)	na	1.8 (56)	0.7 (147)
Ticarcillin–clavulanate	5.4 (92)	na	na	5.4 (92)
Piperacillin–tazobactam	0.0 (93)	na	na	0.0 (93)
Ceftriaxone	0.6 (181)	0.8 (946)	1.9 (53)	0.8 (1180)
Ceftazidime	1.1 (93)	na	na	1.1 (93)
Cefepime	1.1 (93)	na	na	1.1 (93)
Trimethoprim	5.4 (93)	na	3.6 (56)	4.7 (149)
Trimethoprim–sulfamethoxazole	4.9 (103)	4.2 (1443)	na	4.3 (1546)
Gentamicin	0.0 (93)	na	na	0.0 (93)
Tobramycin	0.0 (93)	na	na	0.0 (93)
Amikacin	0.0 (93)	na	na	0.0 (93)
Ciprofloxacin	1.1 (179)	0.2 (936)	0.0 (46)	0.3 (1161)
Norfloxacin	10.8 (93)	1.4 (1087)	0.9 (109)	2.0 (1289)
Nitrofurantoin	8.6 (93)	na	na	8.6 (93)
Meropenem	0.0 (93)	na	na	0.0 (93)

na = not available (either not tested or tested against an inadequate number of isolates)

Sources: OrgTRx (Queensland); AGAR (national); SNP (Queensland and northern New South Wales)